PRODUCTS
SERVICES
COMPANY
CONTACT
FAQ
Search
Dictionary
Mobile
Login
Login/Nickname:
Password:
Remember login
Login
Send password reminder...
Takuya Moriya Selected Research
Carcinoma (Carcinomatosis)
07/2008
Aromatase in human breast carcinoma as a key regulator of intratumoral sex steroid concentrations.
02/2008
Intracrinology of estrogens and androgens in breast carcinoma.
01/2008
Giant T4 rectal carcinoma mimicking urinary bladder adenocarcinoma accurately diagnosed by immunohistochemistry and successfully treated with total pelvic exenteration: Report of a case.
10/2007
Analysis of surrogate markers for target-specific therapy in breast carcinomas using archival materials.
09/2007
In situ production of sex steroids in human breast carcinoma.
08/2007
Progression-free survival and overall survival of patients with clear cell carcinoma of the ovary treated with paclitaxel-carboplatin or irinotecan-cisplatin: retrospective analysis.
06/2007
[Recent evidence about aromatase in the breast carcinoma]
06/2007
Early growth responsive gene 3 in human breast carcinoma: a regulator of estrogen-meditated invasion and a potent prognostic factor.
05/2007
Nuclear cyclin B1 in human breast carcinoma as a potent prognostic factor.
05/2007
Ovarian epithelial carcinoma with estrogen-producing stroma.
03/2007
Comparison of evaluations for hormone receptors in breast carcinoma using two manual and three automated immunohistochemical assays.
01/2007
5Alpha-reductase type 1 and aromatase in breast carcinoma as regulators of in situ androgen production.
12/2006
Adjuvant chemotherapy with irinotecan hydrochloride and cisplatin for clear cell carcinoma of the ovary.
04/2005
Immunolocalization of nuclear transcription factors, DAX-1 and Ad4BP/SF-1, in human common epithelial ovarian tumors: correlations with StAR and steroidogenic enzymes in epithelial ovarian carcinoma.
04/2005
StAR and progesterone producing enzymes (3beta-hydroxysteroid dehydrogenase and cholesterol side-chain cleavage cytochromes P450) in human epithelial ovarian carcinoma: immunohistochemical and real-time PCR studies.
07/2004
Estrogen-related receptor alpha in human breast carcinoma as a potent prognostic factor.
09/2003
Steroid sulfatase and estrogen sulfotransferase in normal human tissue and breast carcinoma.
06/2003
Estrogen sulfotransferase and steroid sulfatase in human breast carcinoma.
04/2003
Pathological assessment of intraductal spread of carcinoma in relation to surgical margin state in breast-conserving surgery.
01/2002
In situ production of estrogens in human breast carcinoma.
Articles by Research Topic
Disease
20
Carcinoma (Carcinomatosis)
07/2008 - 01/2002
10
Breast Neoplasms (Breast Cancer)
02/2008 - 01/2003
4
Neoplasms (Cancer)
10/2008 - 07/2002
3
Prostatic Neoplasms (Prostate Cancer)
12/2007 - 03/2005
3
Ovarian Neoplasms (Ovarian Cancer)
07/2007 - 12/2005
2
Endometrial Neoplasms (Endometrial Cancer)
06/2008 - 06/2003
2
Thymoma (Thymic Carcinoma)
09/2005 - 05/2003
1
Noninfiltrating Intraductal Carcinoma (DCIS)
03/2008
1
Adenocarcinoma
01/2008
1
Pancreatic Neoplasms (Pancreatic Cancer)
01/2008
1
Endometriosis (Adenomyosis)
10/2007
1
Systemic Scleroderma (Systemic Sclerosis)
09/2007
1
Tissue Adhesions
09/2007
1
Germ Cell and Embryonal Neoplasms (Germ Cell Tumor)
06/2007
1
Neoplasm Metastasis (Metastasis)
04/2006
1
Colonic Neoplasms (Colon Cancer)
04/2006
1
Pulmonary Alveolar Proteinosis
04/2006
1
Small Cell Carcinoma
07/2005
1
Thyroid Neoplasms (Thyroid Cancer)
03/2003
1
Interstitial Lung Diseases (Interstitial Lung Disease)
01/2003
Drug/Important Bio-Agent (IBA)
9
Estrogens (Estrogen)
FDA Link
02/2008 - 01/2002
5
Aromatase (CYP19)
IBA
07/2008 - 01/2005
5
Enzymes
IBA
03/2008 - 03/2005
4
Hormones
IBA
03/2007 - 05/2003
3
Steryl-Sulfatase (Steroid Sulfatase)
IBA
06/2006 - 06/2003
3
estrone sulfotransferase
IBA
06/2006 - 06/2003
3
Progesterone Receptors (Progesterone Receptor)
IBA
07/2005 - 07/2002
2
Steroids
IBA
03/2008 - 09/2007
2
irinotecan (Camptosar)
FDA Link
Generic
08/2007 - 12/2006
2
Cisplatin (Platino)
FDA Link
Generic
08/2007 - 12/2006
1
Keratins (Keratin)
IBA
10/2008
1
Vimentin
IBA
10/2008
1
tensins (tensin)
IBA
06/2008
1
beta Catenin
IBA
06/2008
1
Androgens
IBA
02/2008
1
capecitabine (Xeloda)
FDA Link
02/2008
1
Dihydrouracil Dehydrogenase (NADP) (Dihydropyrimidine Dehydrogenase)
IBA
02/2008
1
Thymidine Phosphorylase
IBA
02/2008
1
Granulocyte Colony-Stimulating Factor (G-CSF)
IBA
01/2008
1
Gonadotropin-Releasing Hormone (GnRH)
FDA Link
10/2007
1
Biological Markers (Surrogate Marker)
IBA
10/2007
1
Gelatin
IBA
09/2007
1
Polyglycolic Acid (Polyglycolide)
IBA
09/2007
1
Paclitaxel (Taxol)
FDA Link
Generic
08/2007
1
Carboplatin (JM8)
FDA Link
Generic
08/2007
1
Doxorubicin (Adriamycin)
FDA Link
Generic
07/2007
1
DNA methyltransferase 3A
IBA
06/2007
1
cyclin B1
IBA
05/2007
1
Cyclins
IBA
03/2007
1
Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)
IBA
04/2006
1
titanium silicide (TS-1)
IBA
04/2006
1
Oxidoreductases
IBA
04/2005
1
Cytochromes
IBA
04/2005
1
Transcription Factors (Transcription Factor)
IBA
04/2005
1
Cholesterol
IBA
04/2005
1
Progesterone
FDA Link
Generic
04/2005
1
ERRalpha estrogen-related receptor
IBA
07/2004
1
Biological Tumor Markers (Tumor Markers)
IBA
01/2004
1
3 (or 17)-beta-hydroxysteroid dehydrogenase
IBA
06/2003
1
progesterone receptor B
IBA
06/2003
1
Parathyroid Hormone-Related Protein
IBA
03/2003
1
Medroxyprogesterone 17-Acetate (Depo-Provera)
FDA Link
Generic
03/2003
1
Interleukin-6 (Interleukin 6)
IBA
03/2003
1
gefitinib (Iressa)
FDA Link
01/2003
1
Carcinoembryonic Antigen
IBA
01/2003
1
Protein Isoforms (Isoforms)
IBA
07/2002
Therapy/Procedure
1
Pelvic Exenteration
01/2008
1
Oncolytic Virotherapy
12/2007
1
Gastric Bypass (Roux-en-Y Gastric Bypass)
09/2007
1
Adjuvant Chemotherapy
12/2006
1
Segmental Mastectomy (Lumpectomy)
04/2003